Study on the Value of Non-invasive Dual-Pet Information in Subtype of Metastatic Breast Cancer

Fudan University

Status: Unknown

Conditions: Breast Cancer

Treatments: Procedure: biopsy or surgical pathology in metastases; Drug: 68Ga-HER2 affibody,18F-FDG, 18F-FES

Study type: Observational

Funder types: Other

Identifiers

NCT04758416

STANDPOINT

Details and patient eligibility

About

Study on the Value of Non-invasive Dual-Pet(18F-FES PET and 68Ga-HER2-Affibody PET) Information in Subtype of Metastatic Breast Cancer

Full description

A Phase II, Single-center STudy on the vAlue of Non-invasive Dual-Pet（18F-FES PET and 68Ga-HER2-Affibody PET）InformatiOn IN Subtype of Metastatic Breast Cancer(MBC)

Enrollment: 50 estimated patients

Sex: Male

Ages: 18 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Subjects voluntarily joined the study, signed informed consent, and had good compliance.
2. Female patients aged over 18 years (including cutoff value).
3. an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
4. Recurrence or metastatic breast cancer confirmed by histopathology, or expect to be feasible metastasis puncture or surgery to confirm histopathological recurrence or metastatic breast cancer.

Exclusion criteria

1. Pregnancy or lactation.
2. Alcohol allergy is not suitable for FES-PET/ C.
3. There are contraindications for patients who are expected to have metastasis puncture or surgery.
4. Mental disorders or other conditions affecting patient compliance.

Trial design

50 participants in 1 patient group

Metastatic breast cancer patients

Description:

50 metastatic breast cancer patients

Treatment:

Drug: 68Ga-HER2 affibody,18F-FDG, 18F-FES

Procedure: biopsy or surgical pathology in metastases